peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== History == “Synthesize a multi-component mixture of compounds in a single process and screen it also a single process”. This is the principle of combinatorial chemistry invented by Prof. Furka Á. (Eötvös Loránd University Budapest Hungary) in 1982, and described it including the method of synthesis of combinatorial libraries and that of a deconvolution strategy in a document notarized in the same year. Motivations that led to the invention had been published in 2002. DNA encoded chemical libraries (DECLs) are synthesized by the combinatorial chemistry principle and it clearly agrees with their application.
=== Depression === In meta-analyses, sertraline efficacy is similar to that of other SSRI antidepressants, with an odds ratio for response in clinical depression of between 1.44 and 1.67. However, as with other antidepressants, the nature and clinical significance of this effect remain disputed. A major study of sertraline in a broad primary care population found improvements in general mental health, quality of life, and anxiety. However, it failed to find significant effects on depression in either the mildly or severely depressed, and the clinical relevance and accuracy of the positive effects found have been questioned. In several double-blind studies, sertraline was consistently more effective than placebo for dysthymia, a more chronic variety of depression, and comparable to imipramine in that respect. Sertraline also improves the functional impairments of dysthymia to a similar degree whether group cognitive behavioral therapy is undergone or not. Limited pediatric data also demonstrates a reduction in depressive symptoms in the pediatric population, though it remains a second-line therapy after fluoxetine.
The Portuguese colonial administration in Brazil had two objectives that would ensure colonial order and the monopoly of Portugal's wealthiest and largest colony: to keep under control and eradicate all forms of slave rebellion and resistance, such as the Quilombo of Palmares, and to repress all movements for autonomy or independence, such as the Inconfidência Mineira (1789).
== Collins English Dictionary == The Collins English Dictionary has announced a Word of the Year every year since 2013, and prior to this, announced a new 'word of the month' each month in 2012. Published in Glasgow, UK, Collins English Dictionary has been publishing English dictionaries since 1819. Toward the end of each calendar year, Collins release a shortlist of notable words or those that have come to prominence in the previous 12 months. The shortlist typically comprises ten words, though in 2014 only four words were announced as the Word of the Year shortlist. The Collins Words of the Year are selected by the Collins Dictionary team across Glasgow and London, consisting of lexicographers, editorial, marketing, and publicity staff, though previously the selection process has been open to the public. Whilst the word is not required to be new to feature, the appearance of words in the list is often supported by usage statistics and cross-reference against Collins' extensive corpus to understand how language may have changed or developed in the previous year. The Collins Word of the Year is also not restricted to UK language usage, and words are often chosen that apply internationally as well, for example, fake news in 2017.
Sources: en.wikipedia.org
First, the nucleophilicity of Ser-195 is enhanced by general-base catalysis in which the proton of the serine hydroxyl group is transferred to the imidazole moiety of His-57 during its attack on the electron-deficient carbonyl carbon of the protein-substrate main chain (k1 step). This occurs via the concerted action of the three-amino-acid residues in the catalytic triad. The buildup of negative charge on the resultant tetrahedral intermediate is stabilized in the enzyme's active site's oxyanion hole, by formation of two hydrogen bonds to adjacent main-chain amide-hydrogens. The His-57 imidazolium moiety formed in the k1 step is a general acid catalyst for the k-1 reaction. However, evidence for similar general-acid catalysis of the k2 reaction (Tet2) has been controverted; apparently water provides a proton to the amine leaving group. Breakdown of Tet1 (via k3) generates an acyl enzyme, which is hydrolyzed with His-57 acting as a general base (kH2O) in formation of a tetrahedral intermediate, that breaks down to regenerate the serine hydroxyl moiety, as well as the protein fragment with the newly formed carboxyl terminus.
pork supply chain by 2022 and worked with its suppliers and The Humane Society of the United States (HSUS) to support implementation. While it pledged to publish progress reports in 2018 and 2020, none were released, and as of 2025, the company no longer maintains a public commitment to eliminate gestation crates. In 2013, the Dunkin' Donuts chain in Thailand used an advertisement that contained a photograph of a woman in black facepaint, in order to promote its new chocolate-flavored doughnuts. The company was criticized for the advertisement, with the Human Rights Watch calling it "bizarre and racist". The headquarters in the United States apologized for the advertisement. Nancy Lewis, in Canaan, Connecticut, began a petition in January 2014 to request that Dunkin' Donuts donate their unsold food to local shelters and food banks in her area after seeing her local shop regularly throwing away "large amounts" of unsold food. She said because the company has no official policy on the redistribution of its unsold food items to shelters or food banks, and employees are not allowed to take any home, many affiliates throw all of the goods away. In August 2024, a group of Trump supporters called for a boycott of Dunkin' Donuts for declining advertisements from Rumble for promoting right-wing populism. They also accused the company of being "woke". In January 2025, donut manufacturer FGF Brands, LLC recalled 2 million donuts for Listeria contamination, some of which were sold by Dunkin' Donuts.
=== Breeding === The male builds a floating bubble nest in which the eggs are laid. Unlike other bubble nest builders, males will incorporate bits of plants, twigs, and other debris, which hold the nest together better. The water level should be reduced to 7–10 cm (3–4 in) during spawning, and the temperature should be approximately 28–30 °C (86 °F). Vegetation is essential, as males build their bubble nest using plant material, which they bind together with bubbles. Nests are very elaborate and sturdy, reaching several inches across and an inch deep. Limnophila aquatica, Riccia fluitans, Ceratopteris thalictroides, and Vesicularia dubyana, are good choices for the breeding tank. Peat fiber may also be offered as building material. Once the nest has been built the male will begin courting the female, usually in the afternoon or evening. He signals his intentions by swimming around the female with flared fins, attempting to draw her to the nest where he will continue his courting display. If the female accepts the male she will begin swimming in circles with the male beneath the bubble nest. When she is ready to spawn she touches the male on either the back or the tail with her mouth. Upon this signal the male will embrace the female, turning her first on her side and finally on her back. At this point the female will release approximately five dozen clear eggs, which are immediately fertilized by the male. Most of the eggs will float up into the bubble nest. Eggs that stray are collected by the male and placed in the nest.
Sources: en.wikipedia.org
==== Rwanda ==== Zipline operates two distribution centers in Rwanda. Zipline began deliveries at its first distribution center in Muhanga in October 2016. In 2018, the Rwandan government signed a new deal to build a second distribution center near Kayonza, in the eastern part of the country. This deal expanded Zipline's service to include smaller health centers and hospitals and deliver vaccines and other medical products and blood products. Zipline opened the Kayonza distribution center in December 2018. The company hoped this would bring coverage to 80 percent of the country. Rwanda has mountainous geography and poor road conditions, making an aerial delivery system more efficient than the use of land vehicles. The cost of delivery via drone is comparable to that of delivery by road, especially in emergencies. A 2022 study found that Zipline's service in Rwanda leads to faster delivery times relative to existing ground transportation and less blood component wastage in health facilities. The study found that Zipline's drone delivery service in Rwanda shortened blood product delivery times by 61 percent, reduced blood unit expirations by 67 percent, and was frequently used in response to medical emergencies, with 43 percent of orders being emergency orders.
It appears that this gene loss has happened several times independently in evolutionary separated groups of animals. Lack of ghrelin and MBOAT4 may be relevant to the way that these reptiles can live at a low energy demand for months or years. Their fat stores are used at a low level. The presence of many mutations in genes for aspects of mitochondrial function in these animals may also be involved in their reduced energy demand.
== Developments == A water-soluble prodrug, fospropofol, has been developed and tested with positive results. Fospropofol is rapidly broken down by the enzyme alkaline phosphatase to form propofol. Marketed as Lusedra, this formulation may not produce the pain at the injection site that often occurs with the conventional form of the drug. The U.S. Food and Drug Administration (FDA) approved the product in 2008. By incorporation of an azobenzene unit, a photoswitchable version of propofol (AP2) was developed in 2012 that allows for optical control of GABAA receptors with light. In 2013, a propofol binding site on mammalian GABAA receptors has been identified by photolabeling using a diazirine derivative. Additionally, it was shown that the hyaluronan polymer present in the synovia can be protected from free-radical depolymerization by propofol. Ciprofol is another derivative of propofol that is 4–6 times more potent than propofol. As of 2022 it is undergoing Phase III trials. Ciprofol appears to have a lower incidence of injection site pain and respiratory depression than propofol. Propofol has also been studied for treatment resistant depression.
=== Alkanes === For linear alkanes, molecular ion peaks are often observed. However, for long chain compounds, the intensity of the molecular ion peaks are often weak. Linear fragments often differ by 14 Da (CH2 = 14). For example, hexane fragmentation patterns. The m/z=57 butyl cation is the base peak, and other most abundant peaks in the spectrum are alkyl carbocations at m/z=15, 29, 43 Da.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.